SCHEMBL6429415

SCHEMBL6429415

CCCCCCC=CCCCCCCCC(=O)OC(C)C

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.79
PRKCA P17252 2/20 0.62
PRKCE Q02156 1/20 0.62
PRKCQ Q04759 1/20 0.62
PRKCD Q05655 1/20 0.62
FAAH O00519 3/20 0.59
MAPT P10636 3/20 0.59
ALDH1A1 P00352 1/20 0.59
HPGD P15428 1/20 0.59
CNR1 P21554 1/20 0.59
CNR2 P34972 1/20 0.59
TERT O14746 3/20 0.58
PTPN1 P18031 3/20 0.58
PPARG P37231 3/20 0.58
PPARD Q03181 3/20 0.58
PPARA Q07869 3/20 0.58
CYP1A2 P05177 2/20 0.58
CYP2C19 P33261 2/20 0.58
BLM P54132 2/20 0.58
HSD17B10 Q99714 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL80898 1.00 LMNA (0.79) LMNAPRKCAPRKCEPRKCQPRKCD
SCHEMBL10338455 1.00 LMNA (0.79) LMNAPRKCAPRKCEPRKCQPRKCD
SCHEMBL18133442 1.00 LMNA (0.79) LMNAPRKCAPRKCEPRKCQPRKCD
SCHEMBL10338452 1.00 LMNA (0.79) LMNAPRKCAPRKCEPRKCQPRKCD
SCHEMBL6514796 1.00 LMNA (0.79) LMNAPRKCAPRKCEPRKCQPRKCD
SCHEMBL61998 1.00 LMNA (0.79) LMNAPRKCAPRKCEPRKCQPRKCD
SCHEMBL3656513 1.00 LMNA (0.79) LMNAPRKCAPRKCEPRKCQPRKCD
SCHEMBL6514791 1.00 LMNA (0.79) LMNAPRKCAPRKCEPRKCQPRKCD
SCHEMBL4124375 1.00 LMNA (0.79) LMNAPRKCAPRKCEPRKCQPRKCD
SCHEMBL28578863 1.00 LMNA (0.79) LMNAPRKCAPRKCEPRKCQPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023180560-A1 COMPOSITION FOR ENHANCING KERATIN FIBERS WELLA GERMANY GMBH (DE) 2023-09-28 WO claimed
US-20250354765-A1 SYSTEMS AND METHODS FOR MANAGING THERMAL ENERGY PHASESTOR LLC (US) 2025-11-20 US disclosed
EP-3948138-B1 THERMAL MANAGEMENT DEVICES AND METHODS PHASE CHANGE ENERGY SOLUTIONS INC (US) 2025-11-12 EP disclosed
EP-4042086-B1 SYSTEMS AND METHODS FOR MANAGING THERMAL ENERGY PHASESTOR LLC (US) 2025-09-03 EP disclosed
US-12372289-B2 Temperature control cart for a payload VESTURE LLC (US) 2025-07-29 US disclosed
US-20250207841-A1 TEMPERATURE CONTROL CART FOR A PAYLOAD VESTURE LLC (US) 2025-06-26 US disclosed
US-20250207867-A1 THERMAL ENERGY STORAGE SYSTEMS PHASESTOR LLC (US) 2025-06-26 US disclosed
US-20250207845-A1 PRODUCT TRANSPORT CONTAINERS VESTURE LLC (US) 2025-06-26 US disclosed
US-12320583-B2 Systems for storing and/or transporting temperature-sensitive payloads PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2025-06-03 US disclosed
US-20250172320-A1 CHARGING SYSTEM AND CHARGING CRADLE FOR FOOD TRANSPORTATION SYSTEMS VESTURE LLC (US) 2025-05-29 US disclosed
WO-2017040591-A1 MODULAR AND PORTABLE FIXTURES CONTAINING A PHASE CHANGE MATERIAL PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2017-03-09 WO disclosed
US-20150204618-A1 THERMAL ENERGY STORAGE SYSTEMS PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2015-07-23 US disclosed
EP-2885591-A1 THERMAL ENERGY STORAGE SYSTEMS Phase Change Energy Solutions, Inc. (US) 2015-06-24 EP disclosed
WO-2014031605-A1 THERMAL ENERGY STORAGE SYSTEMS PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2014-02-27 WO disclosed
US-20050043402-A1 Methods and formulations for counteracting infection of mucosa or skin LIPOMEDICA EHF. (IS) 2005-02-24 US disclosed
US-6596763-B1 Method for counteracting infections caused by bacteria, fungi or virus such as Herpes Simplex Virus in skin or mucosal membranes, in particular genital membranes, of a mammal. The method comprises topically administering to skin or mucous LIPOMEDICA EHF. (IS) 2003-07-22 US disclosed
EP-0941087-A1 TOPICAL FORMULATIONS CONTAINING AS A THERAPEUTIC ACTIVE AGENT FATTY ACIDS OR FATTY ALCOHOLS OR MONOGLYCERIDE DERIVATIVES THEREOF FOR TREATING OF MUCOSA INFECTIONS Thormar, Halldor (IS) 1999-09-15 EP disclosed
WO-1998020872-A1 TOPICAL FORMULATIONS CONTAINING AS A THERAPEUTIC ACTIVE AGENT FATTY ACIDS OR FATTY ALCOHOLS OR MONOGLYCERIDE DERIVATIVES THEREOF FOR TREATING OF MUCOSA INFECTIONS THORMAR HALLDOR (IS) 1998-05-22 WO disclosed
US-5391548-A Transdermal flux enhancing compositions to treat hypertension, diabetes and angina pectoris PFIZER INC. (US) 1995-02-21 US disclosed
US-5196410-A Penetration agents PFIZER INC. (US) 1993-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043402-A1 Methods and formulations for counteracting infection of mucosa or skin MGLL, GK, UGCG LMNA 2910/4885PRKCA 2219/4885PRKCE 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.